Although US mortality rates from concurrent HIV and viral hepatitis infection have declined since the late 1990s, gender disparities persist.

Hospital-onset antimicrobial-resistant infections increased across US hospitals during and beyond the COVID-19 pandemic.

Data from a phase 3 study indicated the microbiota-based live biotherapeutic RBL was safe and efficacious for recurrent CDI prevention in immunocompromised patients.

More United States children have died from influenza this season than in any year since the 2009 swine flu pandemic.

Catheter salvage therapy was preferred over CVL removal for CLABSI management in pediatric patients with SBS on long-term TPN.